Molecular biomarkers of depression

Neuroscience and Biobehavioral Reviews

Volumn 64, Issue , 2016, Pages 101-133

  Gururajan, Anand ^a   Clarke, Gerard ^a,b   Dinan, Timothy G ^a,b   Cryan, John F ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Biomarker; Depression; Genomic; Non coding RNA; Proteomic; Telomere

Indexed keywords

4 AMINOBUTYRIC ACID; ARGONAUTE 1 PROTEIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN; DOPAMINE; FIBROBLAST GROWTH FACTOR; GLUTAMIC ACID; GROWTH FACTOR; LONG UNTRANSLATED RNA; MICRORNA; MITOCHONDRIAL DNA; NERVE GROWTH FACTOR; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; SEROTONIN; TRANSCRIPTION FACTOR CLOCK; VASCULOTROPIN;

4 AMINOBUTYRIC ACID UPTAKE; AGO1 GENE; AUTOPSY; BRAIN BIOPSY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CLOCK GENE; DEPRESSION; DGCR8 GENE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; GABAERGIC TRANSMISSION; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENOMICS; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RNA ANALYSIS; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROTONIN RELEASE; SEROTONINERGIC TRANSMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; TELOMERE; TRANSCRIPTOMICS; URINALYSIS; ANIMAL; METABOLISM;

ANIMALS; BIOMARKERS; DEPRESSIVE DISORDER; HUMANS;

EID: 84959334398     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2016.02.011     Document Type: Review

References (371)

1. Adaikalakoteswari A., Balasubramanyam M., Ravikumar R., Deepa R., Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis 2007, 195:83-89.
2. Alegria M., Chatterji P., Wells K., Cao Z., Chen C.N., Takeuchi D., Jackson J., Meng X.L. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr. Serv. 2008, 59:1264-1272.
3. Alexander R.C., Preskorn S. Clinical pharmacology in the development of new antidepressants: the challenges. Curr. Opin. Pharmacol. 2014, 14:6-10.
4. Alkan C., Sajjadian S., Eichler E.E. Limitations of next-generation genome sequence assembly. Nat. Methods 2011, 8:61-65.
5. Allen A.P., Naughton M., Dowling J., Walsh A., Ismail F., Shorten G., Scott L., McLoughlin D.M., Cryan J.F., Dinan T.G., Clarke G. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J. Affective Disorders 2015, 186:306-311.
6. Alt S.R., Turner J.D., Klok M.D., Meijer O.C., Lakke E.A.J.F., DeRijk R.H., Muller C.P. Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed. Psychoneuroendocrinology 2010, 35:544-556.
7. Anderson H.D., Pace W.D., Libby A.M., West D.R., Valuck R.J. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin. Ther. 2012, 34:113-123.
8. Andrade L., Caraveo-anduaga J.J., Berglund P., Bijl R.V., Graaf R.D., Vollebergh W., Dragomirecka E., Kohn R., Keller M., Kessler R.C., Kawakami N., Kiliç C., Offord D., Bedirhan Ustun T., Wittchen H.-U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int. J. Methods Psychiatr. Res. 2003, 12:3-21.
9. Andrews P.W., Bharwani A., Lee K.R., Fox M., Thomson Jr J.A. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci. Biobehav. Rev. 2015, 51:164-188.
10. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10:345-352.
11. Arango V., Underwood M.D., Boldrini M., Tamir H., Kassir S.A., Hsiung J.J.X., HChen S.-C., Mann J.J. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA Expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 2001, 25:892-903.
12. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J. Clin. Investig. 2013, 123:996-1002.
13. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., Mitchell P.S., Bennett C.F., Pogosova-Agadjanyan E.L., Stirewalt D.L., Tait J.F., Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5003-5008.
14. Aschbacher K., O'Donovan A., Wolkowitz O.M., Dhabhar F.S., Su Y., Epel E. Good stress, bad stress and oxidative stress: insights from anticipatory cortisol reactivity. Psychoneuroendocrinology 2013, 38:1698-1708.
15. Aubert G., Lansdorp P.M. Telomeres and Aging. Physiol. Rev. 2008, 88:557-579.
16. Austin M.C., Janosky J.E., Murphy H.A. Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Mol. Psychiatry 2003, 8:324-332.
17. Bach-Mizrachi H., Underwood M.D., Kassir S.A., Bakalian M.J., Sibille E., Tamir H., Mann J.J., Arango V. Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. Neuropsychopharmacology 2005, 31:814-824.
18. Backes C., Meese E., Lenhof H.-P., Keller A. A dictionary on microRNAs and their putative target pathways. Nucleic Acids Res. 2010, 38:4476-4486.
19. Bai M., Zhu X., Zhang Y., Zhang S., Zhang L., Xue L., Yi J., Yao S., Zhang X. Abnormal hippocampal BDNF and miR-16 expression is associated with depression-like behaviors induced by stress during early life. PLoS One 2012, 7:e46921.
20. Bak L.K., Schousboe A., Waagepetersen H.S. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 2006, 98:641-653.
21. Baker S.G. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J. Natl. Cancer Inst. 2003, 95:511-515.
22. Baker M. In biomarkers we trust?. Nat. Biotechnol. 2005, 23:297-304.
23. Balakathiresan N.S., Chandran R., Bhomia M., Jia M., Li H., Maheshwari R.K. Serum and amygdala microRNA signatures of posttraumatic stress: fear correlation and biomarker potential. J. Psychiatr. Res. 2014, 57:65-73.
24. Barry G. Integrating the roles of long and small non-coding RNA in brain function and disease. Mol. Psychiatry 2014, 19:410-416.
25. Baudry A., Mouillet-Richard S., Schneider B., Launay J.M., Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010, 329:1537-1541.
26. Beauchaine T.P. The role of biomarkers and endophenotypes in prevention and treatment of psychopathological disorders. Biomarker Med. 2009, 3:1-3.
27. Belvederi Murri M., Pariante C., Mondelli V., Masotti M., Atti A.R., Mellacqua Z., Antonioli M., Ghio L., Menchetti M., Zanetidou S., Innamorati M., Amore M. HPA axis and aging in depression: Systematic review and meta-analysis. Psychoneuroendocrinology 2014, 41:46-62.
28. Belzeaux R., Formisano-Treziny C., Loundou A., Boyer L., Gabert J., Samuelian J.C., Feron F., Naudin J., Ibrahim E.C. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J. Psychiatr. Res. 2010, 44:1205-1213.
29. Belzeaux R., Bergon A., Jeanjean V., Loriod B., Formisano-Treziny C., Verrier L., Loundou A., Baumstarck-Barrau K., Boyer L., Gall V., Gabert J., Nguyen C., Azorin J.M., Naudin J., Ibrahim E.C. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl. Psychiatry 2012, 2:e185.
30. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
31. Beretov J., Wasinger V.C., Schwartz P., Graham P.H., Li Y. A standardized and reproducible urine preparation protocol for cancer biomarkers discovery. Biomarker Cancer 2014, 6:21-27.
32. Bergstrom A., Jayatissa M.N., Mork A., Wiborg O. Stress sensitivity and resilience in the chronic mild stress rat model of depression; an in situ hybridization study. Brain Res. 2008, 1196:41-52.
33. Bernard R., Kerman I.A., Thompson R.C., Jones E.G., Bunney W.E., Barchas J.D., Schatzberg A.F., Myers R.M., Akil H., Watson S.J. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 2011, 16:634-646.
34. Bienvenu O.J., Davydow D.S., Kendler K.S. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence. Psychol. Med. 2011, 41:33-40.
35. Biomarker-Definitions-Working-Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
36. Bjelland I., Dahl A.A., Haug T.T., Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J. Psychosomatic Res. 2002, 52:69-77.
37. Bjork K., Sjogren B., Svenningsson P. Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins. Exp. Cell Res. 2010, 316:1351-1356.
38. Blackburn E.H., Epel E.S. Telomeres and adversity: too toxic to ignore. Nature 2012, 490:169-171.
39. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 2005, 6:611-622.
40. Bocchio-Chiavetto L., Bagnardi V., Zanardini R., Molteni R., Nielsen M.G., Placentino A., Giovannini C., Rillosi L., Ventriglia M., Riva M.A., Gennarelli M. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry 2010, 11:763-773.
41. Bocchio-Chiavetto L., Maffioletti E., Bettinsoli P., Giovannini C., Bignotti S., Tardito D., Corrada D., Milanesi L., Gennarelli M. Blood microRNA changes in depressed patients during antidepressant treatment. Eur. Neuropsychopharmacol. 2013, 23:602-611.
42. Boldrini M., Underwood M.D., Mann J.J., Arango V. More tryptophan hydroxylase in the brainstem dorsal raphe nucleus in depressed suicides. Brain Res. 2005, 1041:19-28.
43. Bond C.S., Fox A.H. Paraspeckles: nuclear bodies built on long noncoding RNA. J. Cell. Biol. 2009, 186:637-644.
44. Bonkale W.L., Murdock S., Janosky J.E., Austin M.C. Normal levels of tryptophan hydroxylase immunoreactivity in the dorsal raphe of depressed suicide victims. J. Neurochem. 2004, 88:958-964.
45. Borsboom D., Cramer A.O. Network analysis: an integrative approach to the structure of psychopathology. Ann. Rev. Clin. Psychol. 2013, 9:91-121.
46. Branchi I., Santarelli S., Capoccia S., Poggini S., D'Andrea I., Cirulli F., Alleva E. Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. PLoS One 2013, 8:e62226.
47. Brouwer J.P., Appelhof B.C., van Rossum E.F., Koper J.W., Fliers E., Huyser J., Schene A.H., Tijssen J.G., Van Dyck R., Lamberts S.W., Wiersinga W.M., Hoogendijk W.J. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006, 31:1154-1163.
48. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 2008, 11:1169-1180.
49. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharm. Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP) 2008, 11:1169-1180.
50. Burke H.M., Davis M.C., Otte C., Mohr D.C. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 2005, 30:846-856.
51. Burnashev N., Szepetowski P. NMDA receptor subunit mutations in neurodevelopmental disorders. Curr. Opin. Pharmacol. 2015, 20:73-82.
52. Bus B.A.A., Molendijk M.L., Tendolkar I., Penninx B.W.J.H., Prickaerts J., Elzinga B.M., Voshaar R.C.O. Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. Mol. Psychiatry 2015, 20:602-608.
53. Cai N., Chang S., Li Y., Li Q., Hu J., Liang J., Song L., Kretzschmar W., Gan X., Nicod J., Rivera M., Deng H., Du B., Li K., Sang W., Gao J., Gao S., Ha B., Ho H.-Y., Hu C., Hu J., Hu Z., Huang G., Jiang G., Jiang T., Jin W., Li G., Li K., Li Y., Li Y., Li Y., Lin Y.-T., Liu L., Liu T., Liu Y., Liu Y., Lu Y., Lv L., Meng H., Qian P., Sang H., Shen J., Shi J., Sun J., Tao M., Wang G., Wang G., Wang J., Wang L., Wang X., Wang X., Yang H., Yang L., Yin Y., Zhang J., Zhang K., Sun N., Zhang W., Zhang X., Zhang Z., Zhong H., Breen G., Wang J., Marchini J., Chen Y., Xu Q., Xu X., Mott R., Huang G.-J., Kendler K., Flint J. Molecular signatures of major depression. Curr. Biol. 2015.
54. Cai N., Li Y., Chang S., Liang J., Lin C., Zhang X., Liang L., Hu J., Chan W., Kendler Kenneth S., Malinauskas T., Huang G.-J., Li Q., Mott R., Flint J. Genetic Control over mtDNA and Its Relationship to Major Depressive Disorder Current Biology. Curr. Biol. 2015, 25:3170-3177.
55. Camkurt M.A., Acar Ş., Coşkun S., Güneş M., Güneş S., Yilmaz M.F., Görür A., Tamer L. Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls. J. Psychiatr. Res. 2015, 69:67-71.
56. Caputo V., Sinibaldi L., Fiorentino A., Parisi C., Catalanotto C., Pasini A., Cogoni C., Pizzuti A. Brain derived neurotrophic factor (BDNF) expression is regulated by microRNAs miR-26a and miR-26b allele-specific binding. PLoS One 2011, 6:e28656.
57. Carpenter L.L., Janicak P.G., Aaronson S.T., Boyadjis T., Brock D.G., Cook I.A., Dunner D.L., Lanocha K., Solvason H.B., Demitrack M.A. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression Anxiety 2012, 29:587-596.
58. Carroll B.J., Cassidy F., Naftolowitz D., Tatham N.E., Wilson W.H., Iranmanesh A., Liu P.Y., Veldhuis J.D. Pathophysiology of hypercortisolism in depression. Acta Psychiatr. Scand. 2007, 115:90-103.
59. Casacalenda N., Perry J.C., Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am. J. Psychiatry 2002, 159:1354-1360.
60. Castren E., Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 2010, 70:289-297.
61. Catalán R., Gallart J.M., Castellanos J.M., Galard R. Plasma corticotropin-releasing factor in depressive disorders. Biol. Psychiatry 1998, 44:15-20.
62. Cattaneo A., Bocchio-Chiavetto L., Zanardini R., Milanesi E., Placentino A., Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int. J. Neuropsychopharmacol. 2010, 13:103-108.
63. Cattaneo A., Sesta A., Calabrese F., Nielsen G., Riva M.A., Gennarelli M. The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 2010, 35:1423-1428.
64. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., Craig I.W., Anacker C., Zunsztain P.A., McGuffin P., Pariante C.M. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013, 38:377-385.
65. Chang C.K., Hayes R.D., Broadbent M., Fernandes A.C., Lee W., Hotopf M., Stewart R. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 2010, 10:77.
66. Cheng H.-Y.M., Papp J.W., Varlamova O., Dziema H., Russell B., Curfman J.P., Nakazawa T., Shimizu K., Okamura H., Impey S., Obrietan K. microRNA Modulation of Circadian-clock period and entrainment. Neuron 2007, 54:813-829.
67. Chiba S., Numakawa T., Ninomiya M., Richards M.C., Wakabayashi C., Kunugi H. Chronic restraint stress causes anxiety- and depression-like behaviors downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2012, 39:112-119.
68. Choi J., Fauce S.R., Effros R.B. Reduced telomerase activity in human T lymphocytes exposed to cortisol. Brain Behav. Immun. 2008, 22:600-605.
69. Chubb J.E., Bradshaw N.J., Soares D.C., Porteous D.J., Millar J.K. The DISC locus in psychiatric illness. Mol. Psychiatry 2007, 13:36-64.
70. Clark-Raymond A., Halaris A. VEGF and depression: a comprehensive assessment of clinical data. J. Psychiatr. Res. 2013, 47:1080-1087.
71. Clark M.B., Johnston R.L., Inostroza-Ponta M., Fox A.H., Fortini E., Moscato P., Dinger M.E., Mattick J.S. Genome-wide analysis of long noncoding RNA stability. Genome Res. 2012, 22:885-898.
72. Copeland J.R.M., Beekman A.T.F., Braam A.W., Dewey M.E., Delespaul P., Fuhrer R., Hooijer C., Lawlor B.A., Kivela S.-L., Lobo A., Magnusson H., Mann A.H., Meller I., Prince M.J., Reischies F., Roelands M., Skoog I., Turrina C., deVries M.W., Wilson K.C.M. Depression among older people in Europe: the EURODEP studies. World Psychiatry 2004, 3:45-49.
73. Cosco T.D., Doyle F., Ward M., McGee H. Latent structure of the hospital anxiety and depression scale: a 10-year systematic review. J. Psychosomatic Res. 2012, 72:180-184.
74. Costello J., Erkanli A., Angold A. Is there an epidemic of child or adolescent depression. J. Child Psychol. Psychiatry 2006, 47:1263-1271.
75. Cryan J.F., Slattery D.A. GABAB receptors and depression. Current status. Adv. Pharmacol. (San Diego Calif.) 2010, 58:427-451.
76. D'Addario C., Dell'Osso B., Galimberti D., Palazzo M.C., Benatti B., Di Francesco A., Scarpini E., Altamura A.C., Maccarrone M. Epigenetic modulation of BDNF gene in patients with major depressive disorder. Biol. Psychiatry 2013, 73:e6-e7.
77. Daber R., Sukhadia S., Morrissette J.J.D. Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets. Cancer Genet. 2013, 206:441-448.
78. Dager S.R., Oskin N.M., Richards T.L., Posse S. Research Applications of Magnetic Resonance Spectroscopy (MRS) to Investigate Psychiatric Disorders. Top. Magn. Reson. Imaging: TMRI 2008, 19:81-96.
79. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
80. Dash S., Clarke G., Berk M., Jacka F.N. The gut microbiome and diet in psychiatry: focus on depression. Curr. Opin. Psychiatry 2015, 28:1-6.
81. Davis B.N., Hata A. Regulation of MicroRNA biogenesis: a miRiad of mechanisms. Cell Commun. Signal. CCS 2009, 7:18.
82. de la Escosura-Muniz A., Merkoci A. Electrochemical detection of proteins using nanoparticles: applications to diagnostics. Expert Opin. Med. Diagn. 2010, 4:21-37.
83. Dedovic K., Ngiam J. The cortisol awakening response and major depression: examining the evidence. Neuropsychiatr. Dis. Treatment 2015, 11:1181-1189.
84. Devanand D.P., Shapira B., Petty F., Kramer G., Fitzsimons L., Lerer B., Sackeim H.A. Effects of electroconvulsive therapy on plasma GABA. Convulsive Ther. 1995, 11:3-13.
85. Dias C., Feng J., Sun H., Shao N.Y., Mazei-Robison M.S., Damez-Werno D., Scobie K., Bagot R., LaBonte B., Ribeiro E., Liu X., Kennedy P., Vialou V., Ferguson D., Pena C., Calipari E.S., Koo J.W., Mouzon E., Ghose S., Tamminga C., Neve R., Shen L., Nestler E.J. beta-catenin mediates stress resilience through Dicer1/microRNA regulation. Nature 2014, 516:51-55.
86. Dinan T.G. Inflammatory markers in depression. Curr. Opin. Psychiatry 2009, 22:32-36.
87. Dinan T.G. MicroRNAs as a target for novel antipsychotics: a systematic review of an emerging field. Int. J. Neuropsychopharmacol. 2010, 13:395-404.
88. Dinan T.G., Scott L.V. Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J. Anat. 2005, 207:259-264.
89. Ditzen C., Tang N., Jastorff A.M., Teplytska L., Yassouridis A., Maccarrone G., Uhr M., Bronisch T., Miller C.A., Holsboer F., Turck C.W. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 2012, 37:1013-1025.
90. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
91. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
92. Dunlop D.D., Song J., Lyons J.S., Manheim L.M., Chang R.W. Racial/ethnic differences in rates of depression among preretirement adults. Am. J. Public Health 2003, 93:1945-1952.
93. Dutta A., McKie S., Deakin J.F.W. Ketamine and other potential glutamate antidepressants. Psychiatry Res. 2015, 225:1-13.
94. ECT-Review-Group, Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003, 361:799-808.
95. Elfving B., Plougmann P.H., Wegener G. Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci. Lett. 2010, 474:13-16.
96. Epel E.S., Blackburn E.H., Lin J., Dhabhar F.S., Adler N.E., Morrow J.D., Cawthon R.M. Accelerated telomere shortening in response to life stress. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17312-17315.
97. Ersche K.D., Roiser J.P., Lucas M., Domenici E., Robbins T.W., Bullmore E.T. Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology 2011, 214:779-789.
98. Evans S.J., Choudary P.V., Neal C.R., Li J.Z., Vawter M.P., Tomita H., Lopez J.F., Thompson R.C., Meng F., Stead J.D., Walsh D.M., Myers R.M., Bunney W.E., Watson S.J., Jones E.G., Akil H. Dysregulation of the fibroblast growth factor system in major depression. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15506-15511.
99. Fajardo O., Galeno J., Urbina M., Carreira I., Lima L. Serotonin, serotonin 5-HT(1A) receptors and dopamine in blood peripheral lymphocytes of major depression patients. Int. Immunopharmacol. 2003, 3:1345-1352.
100. Fan H.-M., Sun X.-Y., Guo W., Zhong A.-F., Niu W., Zhao L., Dai Y.-H., Guo Z.-M., Zhang L.-Y., Lu J. Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. J. Psychiatr. Res. 2014, 59:45-52.
101. Fasching P.A., Faschingbauer F., Goecke T.W., Engel A., Häberle L., Seifert A., Voigt F., Amann M., Rebhan D., Burger P., Kornhuber J., Ekici A.B., Beckmann M.W., Binder E.B. Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. J. Psychiatr. Res. 2012, 46:1109-1117.
102. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2009, 33:70-75.
103. Fontella F., Siqueira I., Vasconcellos A., Tabajara A., Netto C., Dalmaz C. Repeated restraint stress induces oxidative damage in rat hippocampus. Neurochem. Res. 2005, 30:105-111.
104. Fox N., Growdon J.H. Biomarkers and surrogates. NeuroRx 2004, 1:181.
105. Frisch A., Postilnick D., Rockah R., Michaelovsky E., Postilnick S., Birman E., Laor N., Rauchverger B., Kreinin A., Poyurovsky M., Schneidman M., Modai I., Weizman R. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol. Psychiatry 1999, 4:389-392.
106. Fuchikami M., Morinobu S., Segawa M., Okamoto Y., Yamawaki S., Ozaki N., Inoue T., Kusumi I., Koyama T., Tsuchiyama K., Terao T. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One 2011, 6:e23881.
107. Galard R., Catalán R., Castellanos J.M., Gallart J.M. Plasma corticotropin-releasing factor in depressed patients before and after the dexamethasone suppression test. Biol. Psychiatry 2002, 51:463-468.
108. Galecki P., Galecka E., Maes M., Chamielec M., Orzechowska A., Bobinska K., Lewinski A., Szemraj J. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J. Affective Disorders 2012, 138:360-366.
109. Gallo A., Tandon M., Alevizos I., Illei G.G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012, 7:e30679.
110. Gapp K., Jawaid A., Sarkies P., Bohacek J., Pelczar P., Prados J., Farinelli L., Miska E., Mansuy I.M. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. Nat. Neurosci. 2014, 17:667-669.
111. Garcia-Rizo C., Fernandez-Egea E., Miller B.J., Oliveira C., Justicia A., Griffith J.K., Heaphy C.M., Bernardo M., Kirkpatrick B. Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naive patients with depression. Brain Behav. Immun. 2013, 28:49-53.
112. Gargis A.S., Kalman L., Berry M.W., Bick D.P., Dimmock D.P., Hambuch T., Lu F., Lyon E., Voelkerding K.V., Zehnbauer B.A., Agarwala R., Bennett S.F., Chen B., Chin E.L.H., Compton J.G., Das S., Farkas D.H., Ferber M.J., Funke B.H., Furtado M.R., Ganova-Raeva L.M., Geigenmüller U., Gunselman S.J., Hegde M.R., Johnson P.L.F., Kasarskis A., Kulkarni S., Lenk T., Liu C.S.J., Manion M., Manolio T.A., Mardis E.R., Merker J.D., Rajeevan M.S., Reese M.G., Rehm H.L., Simen B.B., Yeakley J.M., Zook J.M., Lubin I.M. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat. Biotechnol. 2012, 30. 10.1038/nbt.2403.
113. Gaughran F., Payne J., Sedgwick P.M., Cotter D., Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res. Bull. 2006, 70:221-227.
114. Geaghan M., Cairns M.J. MicroRNA and posttranscriptional dysregulation in psychiatry. Biol. Psychiatry 2014.
115. Gerner R.H., Hare T.A. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am. J. Psychiatry 1981, 138:1098-1101.
116. Gerner R.H., Fairbanks L., Anderson G.M., Young J.G., Scheinin M., Linnoila M., Hare T.A., Shaywitz B.A., Cohen D.J. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am. J. Psychiatry 1984, 141:1533-1540.
117. Goenjian A.K., Bailey J.N., Walling D.P., Steinberg A.M., Schmidt D., Dandekar U., Noble E.P. Association of TPH1, TPH2, and 5HTTLPR with PTSD and depressive symptoms. J. Affective Disorders 2012, 140:244-252.
118. Gold B.I., Bowers M.B., Roth R.H., Sweeney D.W. GABA levels in CSF of patients with psychiatric disorders. Am. J. Psychiatry 1980, 137:362-364.
119. Goodall E.F., Heath P.R., Bandmann O., Kirby J., Shaw P.J. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front. Cell. Neurosci. 2013, 7:178.
120. Gotlib I.H., LeMoult J., Colich N.L., Foland-Ross L.C., Hallmayer J., Joormann J., Lin J., Wolkowitz O.M. Telomere length and cortisol reactivity in children of depressed mothers. Mol. Psychiatry 2015, 20:615-620.
121. Granger D.A., Kivlighan K.T., Fortunato C., Harmon A.G., Hibel L.C., Schwartz E.B., Whembolua G.-L. Integration of salivary biomarkers into developmental and behaviorally-oriented research: problems and solutions for collecting specimens. Physiol. Behav. 2007, 92:583-590.
122. Gray A.L., Hyde T.M., Deep-Soboslay A., Kleinman J.E., Sodhi M.S. Sex differences in glutamate receptor gene expression in major depression and suicide. Mol. Psychiatry 2015, 20:1057-1068.
123. Greenberg B.D., Tolliver T.J., Huang S.-J., Li Q., Bengel D., Murphy D.L. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 1999, 88:83-87.
124. Harmer C.J. Serotonin and emotional processing: does it help explain antidepressant drug action?. Neuropharmacology 2008, 55:1023-1028.
125. Harmer C.J., Goodwin G.M., Cowen P.J. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br. J. Psychiatry 2009, 195:102-108.
126. Hartmann N., Boehner M., Groenen F., Kalb R. Telomere length of patients with major depression is shortened but independent from therapy and severity of the disease. Depression Anxiety 2010, 27:1111-1116.
127. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009, 61:105-123.
128. Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. Int. J. Mol. Sci. 2015, 16:7796-7801.
129. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
130. Hayashi-Takagi A., Vawter M.P., Iwamoto K. Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research. Biol. Psychiatry 2014, 75:920-928.
131. He M., Liu Y., Wang X., Zhang Michael Q., Hannon G.J., Huang Z.J. Cell-type-based analysis of microRNA profiles in the mouse brain. Neuron 2012, 73:35-48.
132. He Y., Zhou Y., Xi Q., Cui H., Luo T., Song H., Nie X., Wang L., Ying B. Genetic variations in microRNA processing genes are associated with susceptibility in depression. DNA Cell Biol. 2012, 31:1499-1506.
133. Herbert J. Cortisol and depression: three questions for psychiatry. Psychol. Med. 2013, 43:449-469.
134. Hillege H.L., Fidler V., Diercks G.F., Van Gilst W.H., De Zeeuw D., Van Veldhuisen D.J., Gans R.O., Janssen W.M., Grobbee D.E., De Jong P.E. Prevention of renal and vascular end stage disease (PREVEND) study group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777-1782.
135. Hoen P.W., de Jonge P., Na B.Y., Farzaneh-Far R., Epel E., Lin J., Blackburn E., Whooley M.A. Depression and leukocyte telomere length in patients with coronary heart disease: data from the Heart and Soul Study. Psychosomatic Med. 2011, 73:541-547.
136. Hoen P.W., Rosmalen J.G., Schoevers R.A., Huzen J., van der Harst P., de Jonge P. Association between anxiety but not depressive disorders and leukocyte telomere length after 2 years of follow-up in a population-based sample. Psychol. Med. 2013, 43:689-697.
137. Holden C. Mental health. Global survey examines impact of depression. Science 2000, 288:39-40.
138. Holtzheimer P.E., Mayberg H.S. Deep brain stimulation for psychiatric disorders. Ann. Rev. Neurosci. 2011, 34:289-307.
139. Hommers L., Domschke K., Deckert J. Heterogeneity and individuality: microRNAs in mental disorders. J. Neural Transm. 2015, 122:79-97.
140. Hong W., Fan J., Yuan C., Zhang C., Hu Y., Peng D., Wang Y., Huang J., Li Z., Yu S., Liu X., Wu Z., Chen J., Yi Z., Xu L., Fang Y. Significantly decreased mRNA levels of BDNF and MEK1 genes in treatment-resistant depression. Neuroreport 2014, 25:753-755.
141. Hopkins M.M., Hogarth S. Biomarker patents for diagnostics: problem or solution?. Nat. Biotechnol. 2012, 30:498-500.
142. Hunsberger J., Austin D., Chen G., Manji H. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromol. Med. 2009, 11:173-182.
143. Iacob E., Light K.C., Tadler S.C., Weeks H.R., White A.T., Hughen R.W., Vanhaitsma T.A., Bushnell L., Light A.R. Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls. BMC Psychiatry 2013, 13:273.
144. Iacob E., Tadler S.C., Light K.C., Weeks H.R., Smith K.W., White A.T., Hughen R.W., VanHaitsma T.A., Bushnell L.A., Light A.R. Leukocyte gene expression in patients with medication refractory depression before and after treatment with ECT or isoflurane anesthesia: a pilot study. Depression Res. Treatment 2014, 2014:582380.
145. Iga J., Ueno S., Yamauchi K., Motoki I., Tayoshi S., Ohta K., Song H., Morita K., Rokutan K., Ohmori T. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci. Lett. 2005, 389:12-16.
146. Iga J., Ueno S., Yamauchi K., Numata S., Tayoshi-Shibuya S., Kinouchi S., Nakataki M., Song H., Hokoishi K., Tanabe H., Sano A., Ohmori T. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2007, 31:658-663.
147. Inder W.J., Prickett T.C., Mulder R.T., Donald R.A., Joyce P.R. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology 2001, 156:73-78.
148. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., Künzel H.E., Pfennig A., Uhr M., Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker?. Biol. Psychiatry 2007, 62:47-54.
149. Issler O., Chen A. Determining the role of microRNAs in psychiatric disorders. Nat. Rev. Neurosci. 2015, 16:201-212.
150. Issler O., Haramati S., Paul E.D., Maeno H., Navon I., Zwang R., Gil S., Mayberg H.S., Dunlop B.W., Menke A., Awatramani R., Binder E.B., Deneris E.S., Lowry C.A., Chen A. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 2014, 83:344-360.
151. Jarosik J., Legutko B., Werner S., Unsicker K., von Bohlen Und Halbach O. Roles of exogenous and endogenous FGF-2 in animal models of depression. Restor. Neurol. Neurosci. 2011, 29:153-165.
152. Joëls M., Karst H., DeRijk R., de Kloet E.R. The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 2008, 31:1-7.
153. Joensuu M., Ahola P., Knekt P., Lindfors O., Saarinen P., Tolmunen T., Valkonen-Korhonen M., Vanninen R., Jaaskelainen T., Virtala E., Kuikka J., Tiihonen J., Lehtonen J. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression. Psychiatry Clin. Neurosci. 2015.
154. Jurk D., Wilson C., Passos J.F., Oakley F., Correia-Melo C., Greaves L., Saretzki G., Fox C., Lawless C., Anderson R., Hewitt G., Pender S.L.F., Fullard N., Nelson G., Mann J., van de Sluis B., Mann D.A., von Zglinicki T. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat. Commun. 2014, 2.
155. Juruena M.F., Pariante C.M., Papadopoulos A.S., Poon L., Lightman S., Cleare A.J. The role of mineralocorticoid receptor function in treatment-resistant depression. J. Psychopharmacol. 2013, 27:1169-1179.
156. Kambeitz J.P., Howes O.D. The serotonin transporter in depression: meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J. Affective Disorders 2015, 186:358-366.
157. Kang H.J., Kawasawa Y.I., Cheng F., Zhu Y., Xu X., Li M., Sousa A.M.M., Pletikos M., Meyer K.A., Sedmak G., Guennel T., Shin Y., Johnson M.B., Krsnik Z., Mayer S., Fertuzinhos S., Umlauf S., Lisgo S.N., Vortmeyer A., Weinberger D.R., Mane S., Hyde T.M., Huttner A., Reimers M., Kleinman J.E., Sestan N. Spatio-temporal transcriptome of the human brain. Nature 2011, 478:483-489.
158. Karabatsiakis A., Kolassa I.T., Kolassa S., Rudolph K.L., Dietrich D.E. Telomere shortening in leukocyte subpopulations in depression. BMC Psychiatry 2014, 14:192.
159. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatry 2005, 57:1068-1072.
160. Karg K., Burmeister M., Shedden K., Sen S. The serotonin transporter promoter variant (5-httlpr), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 2011, 68:444-454.
161. Kasa K., Otsuki S., Yamamoto M., Sato M., Kuroda H., Ogawa N. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol. Psychiatry 1982, 17:877-883.
162. Katz E.R., Stowe Z.N., Newport D.J., Kelley M.E., Pace T.W., Cubells J.F., Binder E.B. Regulation of mRNA expression encoding chaperone and co-chaperone proteins of the glucocorticoid receptor in peripheral blood: association with depressive symptoms during pregnancy. Psychol. Med. 2012, 42:943-956.
163. Kesselheim A.S., Shiu N. The evolving role of biomarker patents in personalized medicine. Clin. Pharmacol. Ther. 2014, 95:127-129.
164. Klok M.D., Alt S.R., Irurzun Lafitte A.J.M., Turner J.D., Lakke E.A.J.F., Huitinga I., Muller C.P., Zitman F.G., Ronald de Kloet E., DeRijk R.H. Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J. Psychiatr. Res. 2011, 45:871-878.
165. Knorr U., Vinberg M., Kessing L.V., Wetterslev J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 2010, 35:1275-1286.
166. Kohen R., Dobra A., Tracy J.H., Haugen E. Transcriptome profiling of human hippocampus dentate gyrus granule cells in mental illness. Transl. Psychiatry 2014, 4:e366.
167. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
168. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 2002, 7(Suppl 1):S71-80.
169. Küçükibrahimoğlu E., Saygin M., Çalişkan M., Kaplan O., Ünsal C., Gören M.Z. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur. J. Clin. Pharmacol. 2009, 65:571-577.
170. Kuhn D.E., Martin M.M., Feldman D.S., Terry A.V., Nuovo G.J., Elton T.S. Experimental Validation of miRNA Targets. Methods 2008, 44:47-54.
171. LaBaer J. So, you want to look for biomarkers. J. Proteome Res. 2005, 4:1053-1059.
172. Labib M., Berezovski M.V. Electrochemical sensing of microRNAs: avenues and paradigms. Biosens. Bioelectr. 2015, 68c:83-94.
173. Lakhan S.E., Vieira K., Hamlat E. Biomarkers in psychiatry: drawbacks and potential for misuse. Int. Arch. Medicine 2010, 3:1.
174. Landgraf P., Rusu M., Sheridan R., Sewer A., Iovino N., Aravin A., Pfeffer S., Rice A., Kamphorst A.O., Landthaler M., Lin C., Socci N.D., Hermida L., Fulci V., Chiaretti S., Foà R., Schliwka J., Fuchs U., Novosel A., Müller R.-U., Schermer B., Bissels U., Inman J., Phan Q., Chien M., Weir D.B., Choksi R., De Vita G., Frezzetti D., Trompeter H.-I., Hornung V., Teng G., Hartmann G., Palkovits M., Di Lauro R., Wernet P., Macino G., Rogler C.E., Nagle J.W., Ju J., Papavasiliou F.N., Benzing T., Lichter P., Tam W., Brownstein M.J., Bosio A., Borkhardt A., Russo J.J., Sander C., Zavolan M., Tuschl T. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129:1401-1414.
175. Launay J.M., Mouillet-Richard S., Baudry A., Pietri M., Kellermann O. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl. Psychiatry 2011, 1:e56.
176. Le-Niculescu H., Kurian S.M., Yehyawi N., Dike C., Patel S.D., Edenberg H.J., Tsuang M.T., Salomon D.R., Nurnberger J.I., Niculescu A.B. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol. Psychiatry 2008, 14:156-174.
177. Leistedt S.J., Linkowski P. Brain, networks, depression, and more. Eur. Neuropsychopharmacol. 2013, 23:55-62.
178. Leonard B.E. The immune system, depression and the action of antidepressants. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2001, 25:767-780.
179. Leung A.K., Sharp P.A. MicroRNA functions in stress responses. Mol. Cell 2010, 40:205-215.
180. Levanon E.Y., Eisenberg E., Yelin R., Nemzer S., Hallegger M., Shemesh R., Fligelman Z.Y., Shoshan A., Pollock S.R., Sztybel D., Olshansky M., Rechavi G., Jantsch M.F. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 2004, 22:1001-1005.
181. Li M., Soczynska J., Kennedy S. Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr. Psychiatry Rep. 2011, 13:316-320.
182. Li Y.J., Xu M., Gao Z.H., Wang Y.Q., Yue Z., Zhang Y.X., Li X.X., Zhang C., Xie S.Y., Wang P.Y. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One 2013, 8:e63648.
183. Liew C.-C., Ma J., Tang H.-C., Zheng R., Dempsey A.A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med. 2006, 147:126-132.
184. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
185. Lima L., Mata S., Urbina M. Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression. Neuroimmunomodulation 2005, 12:299-306.
186. Lima I.M., Barros A., Rosa D.V., Albuquerque M., Malloy-Diniz L., Neves F.S., Romano-Silva M.A., de Miranda D.M. Analysis of telomere attrition in bipolar disorder. J. Affective Disorders 2014, 172c:43-47.
187. Lin K.M. Biological differences in depression and anxiety across races and ethnic groups. J. Clin. Psychiatry 2001, 62(Suppl 13):13-19. discussion 20-11.
188. Lin P.-Y., Tseng P.-T. Decreased glial cell line-derived neurotrophic factor levels in patients with depression: a meta-analytic study. J. Psychiatr. Res. 2015, 63:20-27.
189. Lin D., Pestova T.V., Hellen C.U.T., Tiedge H. Translational control by a small RNA: dendritic BC1 RNA targets the eukaryotic initiation factor 4A helicase mechanism. Mol. Cell. Biol. 2008, 28:3008-3019.
190. Liu J., Wang X., Shigenaga M.K., Yeo H.C., Mori A., Ames B.N. Immobilization stress causes oxidative damage to lipid, protein, and DNA in the brain of rats. FASEB J. 1996, 10:1532-1538.
191. Liu Z., Li X., Sun N., Xu Y., Meng Y., Yang C., Wang Y., Zhang K. Microarray profiling and co-expression network analysis of circulating lncRNAs and mRNAs associated with major depressive disorder. PLoS One 2014, 9:e93388.
192. Liu B.B., Luo L., Liu X.L., Geng D., Liu Q., Yi L.T. 7-Chlorokynurenic acid (7-CTKA) produces rapid antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB-ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress. Psychopharmacology 2015, 232:541-550.
193. Llorca P.-M. Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. J. Psychopharmacol. 2010, 24:21-26.
194. Lopez-Figueroa A.L., Norton C.S., Lopez-Figueroa M.O., Armellini-Dodel D., Burke S., Akil H., Lopez J.F., Watson S.J. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 2004, 55:225-233.
195. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. A.E. Bennett Research Award. Regulation of serotonin1A glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 1998, 43:547-573.
196. Lopez J.P., Lim R., Cruceanu C., Crapper L., Fasano C., Labonte B., Maussion G., Yang J.P., Yerko V., Vigneault E., El Mestikawy S., Mechawar N., Pavlidis P., Turecki G. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat. Med. 2014, 20:764-768.
197. López León S., Croes E.A., Sayed-Tabatabaei F.A., Claes S., Broeckhoven C.V., van Duijn C.M. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis. Biol. Psychiatry 2005, 57:999-1003.
198. Lopresti A.L., Maker G.L., Hood S.D., Drummond P.D. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2014, 48:102-111.
199. Lung F.W., Chen N.C., Shu B.C. Genetic pathway of major depressive disorder in shortening telomeric length. Psychiatr. Genet. 2007, 17:195-199.
200. Luscher B., Shen Q., Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol. Psychiatry 2011, 16:383-406.
201. Maddock R.J., Buonocore M.H. MR spectroscopic studies of the brain in psychiatric disorders. Curr. Top. Behav. Neurosci. 2012, 11:199-251.
202. Magnani F., Tate C.G., Wynne S., Williams C., Haase J. Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin. J. Biol. Chem. 2004, 279:38770-38778.
203. Maheu M., Lopez J.P., Crapper L., Davoli M.A., Turecki G., Mechawar N. MicroRNA regulation of central glial cell line-derived neurotrophic factor (GDNF) signalling in depression. Transl. Psychiatry 2015, 5:e511.
204. Malberg J.E., Monteggia L.M. VGF, a new player in antidepressant action?. Sci. Signal. 2008, 1:pe19.
205. Mamdani F., Rollins B., Morgan L., Myers R.M., Barchas J.D., Schatzberg A.F., Watson S.J., Akil H., Potkin S.G., Bunney W.E., Vawter M.P., Sequeira P.A. Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Transl. Psychiatry 2015, 5:e636.
206. Manki H., Kanba S., Muramatsu T., Higuchi S., Suzuki E., Matsushita S., Ono Y., Chiba H., Shintani F., Nakamura M., Yagi G., Asai M. Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. J. Affective Disorders 1996, 40:7-13.
207. Mann J.J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999, 21:99S-105S.
208. Mannironi C., Camon J., De Vito F., Biundo A., De Stefano M.E., Persiconi I., Bozzoni I., Fragapane P., Mele A., Presutti C. Acute stress alters amygdala microRNA miR-135a and miR-124 expression: inferences for corticosteroid dependent stress response. PLoS One 2013, 8:e73385.
209. Martin-Ruiz C.M., Baird D., Roger L., Boukamp P., Krunic D., Cawthon R., Dokter M.M., van der Harst P., Bekaert S., de Meyer T., Roos G., Svenson U., Codd V., Samani N.J., McGlynn L., Shiels P.G., Pooley K.A., Dunning A.M., Cooper R., Wong A., Kingston A., von Zglinicki T. Reproducibility of telomere length assessment: an international collaborative study. Int. J. Epidemiol. 2014.
210. Martinsson L., Wei Y., Xu D., Melas P.A., Mathe A.A., Schalling M., Lavebratt C., Backlund L. Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl. Psychiatry 2013, 3:e261.
211. Matsubara T., Funato H., Kobayashi A., Nobumoto M., Watanabe Y. Reduced glucocorticoid receptor alpha expression in mood disorder patients and first-degree relatives. Biol. Psychiatry 2006, 59:689-695.
212. Mattick J.S., Amaral P.P., Dinger M.E., Mercer T.R., Mehler M.F. RNA regulation of epigenetic processes. BioEssays 2009, 31:51-59.
213. McGonigle P., Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem. Pharmacol. 2014, 87:162-171.
214. Medina A., Seasholtz A.F., Sharma V., Burke S., Bunney W., Myers R.M., Schatzberg A., Akil H., Watson S.J. Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. J. Psychiatr. Res. 2013, 47:307-314.
215. Meerson A., Cacheaux L., Goosens K.A., Sapolsky R.M., Soreq H., Kaufer D. Changes in brain MicroRNAs contribute to cholinergic stress reactions. J. Mol. Neurosci. MN 2010, 40:47-55.
216. Mendell J.T., Olson E.N. MicroRNAs in stress signaling and human disease. Cell 2012, 148:1172-1187.
217. Menke A., Klengel T., Rubel J., Bruckl T., Pfister H., Lucae S., Uhr M., Holsboer F., Binder E.B. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav. 2013, 12:289-296.
218. Mercer T., Qureshi I., Gokhan S., Dinger M., Li G., Mattick J., Mehler M. Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci. 2010, 11:14.
219. Mergny J.-L., Riou J.-F., Mailliet P., Teulade-Fichou M.-P., Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res. 2002, 30:839-865.
220. Meshorer E., Soreq H. Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci. 2006, 29:216-224.
221. Messias E., Eaton W.W., Grooms A.N. Economic grand rounds: income inequality and depression prevalence across the united states: an ecological study. Psychiatr. Serv. 2011, 62:710-712.
222. Milanesi E., Minelli A., Cattane N., Cattaneo A., Mora C., Barbon A., Mallei A., Popoli M., Florio V., Conca A., Bignotti S., Gennarelli M. ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. BMC Psychiatry 2012, 12:145.
223. Mishra P.J., Bertino J.R. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009, 10:399-416.
224. Molendijk M.L., Spinhoven P., Polak M., Bus B.A.A., Penninx B.W.J.H., Elzinga B.M. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol. Psychiatry 2014, 19:791-800.
225. Monteggia L.M., Zarate C.A. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr. Opin. Neurobiol. 2015, 30:139-143.
226. Morozova O., Hirst M., Marra M.A. Applications of new sequencing technologies for transcriptome analysis. Ann. Rev. Genom. Hum. Genet. 2009, 10:135-151.
227. Mostafavi S., Battle A., Zhu X., Potash J.B., Weissman M.M., Shi J., Beckman K., Haudenschild C., McCormick C., Mei R., Gameroff M.J., Gindes H., Adams P., Goes F.S., Mondimore F.M., MacKinnon D.F., Notes L., Schweizer B., Furman D., Montgomery S.B., Urban A.E., Koller D., Levinson D.F. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Mol. Psychiatry 2014, 19:1267-1274.
228. Moussavi S., Chatterji S., Verdes E., Tandon A., Patel V., Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
229. Müller M.J., Himmerich H., Kienzle B., Szegedi A. Differentiating moderate and severe depression using the Montgomery-Åsberg depression rating scale (MADRS). J. Affective Disorders 2003, 77:255-260.
230. Muller N., Myint A.M., Schwarz M.J. Inflammatory biomarkers and depression. Neurotoxic. Res. 2011, 19:308-318.
231. Murgatroyd C., Quinn J.P., Sharp H.M., Pickles A., Hill J. Effects of prenatal and postnatal depression, and maternal stroking, at the glucocorticoid receptor gene. Transl. Psychiatry 2015, 5:e560.
232. Najjar S., Pearlman D.M., Hirsch S., Friedman K., Strange J., Reidy J., Khoukaz M., Ferrell R.B., Devinsky O., Najjar A., Zagzag D. Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: a case report. Biol. Psychiatry 2014, 75:e23-e26.
233. Nakase S., Kitayama I., Soya H., Hamanaka K., Nomura J. Increased expression of magnocellular arginine vasopressin mRNA in paraventricular nucleus of stress-induced depression-model rats. Life Sci. 1998, 63:23-31.
234. Naughton M., Mulrooney J.B., Leonard B.E. A review of the role of serotonin receptors in psychiatric disorders. Hum. Psychopharmacol. 2000, 15:397-415.
235. Needham B.L., Mezuk B., Bareis N., Lin J., Blackburn E.H., Epel E.S. Depression, anxiety and telomere length in young adults: evidence from the National Health and Nutrition Examination Survey. Mol. Psychiatry 2015.
236. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166:980-991.
237. Nestler E.J. Epigenetic mechanisms of depression. JAMA Psychiatry 2014, 71:454-456.
238. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
239. Niculescu A.B., Le-Niculescu H. Convergent functional genomics: what we have learned and can learn about genes, pathways, and mechanisms. Neuropsychopharmacology 2010, 35:355-356.
240. Norton S., Cosco T., Doyle F., Done J., Sacker A. The hospital anxiety and depression scale: a meta confirmatory factor analysis. J. Psychosomatic Res. 2013, 74:74-81.
241. Notaras M., Hill R., van den Buuse M. The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol. Psychiatry 2015, 20:916-930.
242. O'Connor R.M., Dinan T.G., Cryan J.F. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol. Psychiatry 2012, 17:359-376.
243. O'Connor R.M., Grenham S., Dinan T.G., Cryan J.F. microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int. J. Neuropsychopharmacol. 2013, 16:1885-1892.
244. Oberlander T.F., Weinberg J., Papsdorf M., Grunau R., Misri S., Devlin A.M. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenet. Off. J. DNA Methylation Soc. 2008, 3:97-106.
245. Otsuki K., Uchida S., Watanuki T., Wakabayashi Y., Fujimoto M., Matsubara T., Funato H., Watanabe Y. Altered expression of neurotrophic factors in patients with major depression. J. Psychiatr. Res. 2008, 42:1145-1153.
246. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 1994, 40:288-295.
247. Owens M., Herbert J., Jones P.B., Sahakian B.J., Wilkinson P.O., Dunn V.J., Croudace T.J., Goodyer I.M. Elevated morning cortisol is a stratified population-level biomarker for major depression in boys only with high depressive symptoms. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:3638-3643.
248. Pace T.W., Miller A.H. Cytokines and glucocorticoid receptor signaling: relevance to major depression. Ann. N. Y. Acad. Sci. 2009, 1179:86-105.
249. Pajer K., Andrus B.M., Gardner W., Lourie A., Strange B., Campo J., Bridge J., Blizinsky K., Dennis K., Vedell P., Churchill G.A., Redei E.E. Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression. Transl. Psychiatry 2012, 2:e101.
250. Pandey G.N., Dwivedi Y., Rizavi H.S., Ren X., Zhang H., Pavuluri M.N. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2010, 34:645-651.
251. Papakostas G.I., Shelton R.C., Smith J., Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J. Clin. Psychiatry 2007, 68:826-831.
252. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
253. Paulus M.P. Pragmatism instead of mechanism: a call for impactful biological psychiatry. JAMA psychiatry 2015.
254. Pehrson A.L., Sanchez C. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Design Dev. Ther. 2015, 9:603-624.
255. Pepe M.S., Janes H. Insights into latent class analysis of diagnostic test performance. Biostatistics 2007, 8:474-484.
256. Perlman W.R., Webster M.J., Kleinman J.E., Weickert C.S. Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol. Psychiatry 2004, 56:844-852.
257. Pescosolido B., Martin J., Long S., Medina T., Phelan J., Link B. A disease like any other? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. Am. J. Psychiatry 2010, 167:1321-1330.
258. Petty F., Schlesser M.A. Plasma GABA in affective illness. A preliminary investigation. J. Affective Disorders 1981, 3:339-343.
259. Petty F., Sherman A.D. Plasma GABA levels in psychiatric illness. J. Affective Disorders 1984, 6:131-138.
260. Petty F., Kramer G.L., Dunnam D., Rush A.J. Plasma GABA in mood disorders. Psychopharmacol. Bull. 1990, 26:157-161.
261. Petty F., Kramer G.L., Gullion C.M., Rush A.J. Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol. Psychiatry 1992, 32:354-363.
262. Petty F., Steinberg J., Kramer G.L., Fulton M., Moeller F.G. Desipramine does not alter plasma GABA in patients with major depression. J. Affective Disorders 1993, 29:53-56.
263. Petty F., Kramer G.L., Fulton M., Davis L., Rush A.J. Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biol. Psychiatry 1995, 37:806-810.
264. Phillips A.C., Robertson T., Carroll D., Der G., Shiels P.G., McGlynn L., Benzeval M. Do symptoms of depression predict telomere length?: Evidence from the west of Scotland twenty-07 study. Psychosomatic Med. 2013, 75:288-296.
265. Piccinni A., Marazziti D., Catena M., Domenici L., Del Debbio A., Bianchi C., Mannari C., Martini C., Da Pozzo E., Schiavi E., Mariotti A., Roncaglia I., Palla A., Consoli G., Giovannini L., Massimetti G., Dell'Osso L. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J. Affective Disorders 2008, 105:279-283.
266. Pine D.S., Leibenluft E. BIomarkers with a mechanistic focus. JAMA Psychiatry 2015.
267. Plotsky P.M., Meaney M.J. Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res. Mol. Brain Res. 1993, 18:195-200.
268. Polho G.B., De-Paula V.J., Cardillo G., dos Santos B., Kerr D.S. Leukocyte telomere length in patients with schizophrenia: a meta-analysis. Schizophrenia Res. 2015, 165:195-200.
269. Polyakova M., Stuke K., Schuemberg K., Mueller K., Schoenknecht P., Schroeter M.L. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. Affective Disorders 2015, 174:432-440.
270. Ponjavic J., Oliver P.L., Lunter G., Ponting C.P. Genomic and transcriptional co-localization of protein-coding and long non-coding RNA pairs in the developing brain. PLoS Genet. 2009, 5:e1000617.
271. Post R.M., Ballenger J.C., Hare T.A., Goodwin F.K., Lake C.R., Jimerson D.C., Bunney Jr W.E. Cerebrospinal fluid GABA in normals and patients with affective disorders. Brain Res. Bull. 1980, 5(Suppl 2):755-759.
272. Puterman E., Epel E.S., Lin J., Blackburn E.H., Gross J.J., Whooley M.A., Cohen B.E. Multisystem resiliency moderates the major depression-telomere length association: findings from the Heart and Soul Study. Brain Behav. Immun. 2013, 33:65-73.
273. Qureshi I., Mehler M. Long non-coding RNAs: novel targets for nervous system disease diagnosis and therapy. Neurotherapeutics 2013, 10:632-646.
274. Qureshi I.A., Mattick J.S., Mehler M.F. Long non-coding RNAs in nervous system function and disease. Brain Res. 2010, 1338:20-35.
275. Raadsheer F.C., van Heerikhuize J.J., Lucassen P.J., Hoogendijk W.J., Tilders F.J., Swaab D.F. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am. J. Psychiatry 1995, 152:1372-1376.
276. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-[alpha]: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
277. Rao P., Benito E., Fischer A. MicroRNAs as biomarkers for CNS disease. Front. Mol. Neurosci. 2013, 6:39.
278. Redei E.E., Andrus B.M., Kwasny M.J., Seok J., Cai X., Ho J., Mohr D.C. Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy. Transl. Psychiatry 2014, 4:e442.
279. Ricci A., Bronzetti E., Felici L., Tayebati S.K., Amenta F. Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci. Lett. 1997, 229:130-134.
280. Rinaldi A., Vincenti S., De Vito F., Bozzoni I., Oliverio A., Presutti C., Fragapane P., Mele A. Stress induces region specific alterations in microRNAs expression in mice. Behav. Brain Res. 2010, 208:265-269.
281. Rivera-Baltanas T., Olivares J.M., Calado-Otero M., Kalynchuk L.E., Martinez-Villamarin J.R., Caruncho H.J. Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder. J. Affective Disorders 2012, 137:46-55.
282. Rivera-Baltanas T., Olivares J.M., Martinez-Villamarin J.R., Fenton E.Y., Kalynchuk L.E., Caruncho H.J. Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy. J. Affective Disorders 2014, 163:47-55.
283. Rocc P., De Leo C., Eva C., Marchiaro L., Milani A.M., Musso R., Ravizza L., Zanalda E., Bogetto F. Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2002, 26:1155-1160.
284. Rodgers A.B., Morgan C.P., Bronson S.L., Revello S., Bale T.L. Paternal stress exposure alters sperm microRNA content and reprograms offspring HPA stress axis regulation. J. Neurosci. 2013, 33:9003-9012.
285. Roy A., Dejong J., Ferraro T. CSF GABA in depressed patients and normal controls. Psychol. Med. 1991, 21:613-618.
286. Rufer N., Dragowska W., Thornbury G., Roosnek E., Lansdorp P.M. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat. Biotechnol. 1998, 16:743-747.
287. Rukov J.L., Wilentzik R., Jaffe I., Vinther J., Shomron N. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinf. 2013.
288. Ruo B., Rumsfeld J.S., Hlatky M.A., Liu H., Browner W.S., Whooley M.A. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003, 290:215-221.
289. Sackeim H.A., Rush A.J., George M.S., Marangell L.B., Husain M.M., Nahas Z., Johnson C.R., Seidman S., Giller C., Haines S., Simpson Jr R.K., Goodman R.R. Vagus nerve stimulation (VNS[trade]) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001, 25:713-728.
290. Salton S.R.J., Ferri G.-L., Hahm S., Snyder S.E., Wilson A.J., Possenti R., Levi A. VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front. Neuroendocrinol. 2000, 21:199-219.
291. Saus E., Soria V., Escaramis G., Vivarelli F., Crespo J.M., Kagerbauer B., Menchon J.M., Urretavizcaya M., Gratacos M., Estivill X. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum. Mol. Genet. 2010, 19:4017-4025.
292. Sawada N., Uchida H., Suzuki T., Watanabe K., Kikuchi T., Handa T., Kashima H. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 2009, 9:1-10.
293. Schaakxs R., Verhoeven J.E., Oude Voshaar R.C., Comijs H.C., Penninx B.W.J.H. Leukocyte telomere length and late-life depression. Am. J. Geriatr. Psychiatry 2015, 23:423-432.
294. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol. 2007, 18:391-418.
295. Schon E.A., DiMauro S., Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat. Rev. Genet. 2012, 13:878-890.
296. Scott K.A., Hoban A.E., Clarke G., Moloney G.M., Dinan T.G., Cryan J.F. Thinking small: towards microRNA-based therapeutics for anxiety disorders. Expert Opin. Investig. Drugs 2015, 1-14.
297. Sen S., Duman R., Sanacora G. Serum BDNF, depression and anti-depressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
298. Serra-Millas M., Lopez-Vilchez I., Navarro V., Galan A.M., Escolar G., Penades R., Catalan R., Fananas L., Arias B., Gasto C. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression. Psychopharmacology 2011, 216:1-8.
299. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 2006, 12:247-257.
300. Serretti A., Zanardi R., Cusin C., Rossini D., Lorenzi C., Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur. Neuropsychopharmacol. 2001, 11:375-380.
301. Serretti A., Zanardi R., Rossini D., Cusin C., Lilli R., Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry 2001, 6:586-592.
302. Shaffer J.A., Epel E., Kang M.S., Ye S., Schwartz J.E., Davidson K.W., Kirkland S., Honig L.S., Shimbo D. Depressive symptoms are not associated with leukocyte telomere length: findings from the Nova Scotia Health Survey (NSHS95), a population-based study. PLoS One 2012, 7:e48318.
303. Shalev I., Moffitt T.E., Braithwaite A.W., Danese A., Fleming N.I., Goldman-Mellor S., Harrington H.L., Houts R.M., Israel S., Poulton R., Robertson S.P., Sugden K., Williams B., Caspi A. Internalizing disorders and leukocyte telomere erosion: a prospective study of depression, generalized anxiety disorder and post-traumatic stress disorder. Mol. Psychiatry 2014, 19:1163-1170.
304. Shaltiel G., Hanan M., Wolf Y., Barbash S., Kovalev E., Shoham S., Soreq H. Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain Struct. Funct. 2013, 218:59-72.
305. Simon N.M., Smoller J.W., McNamara K.L., Maser R.S., Zalta A.K., Pollack M.H., Nierenberg A.A., Fava M., Wong K.K. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol. Psychiatry 2006, 60:432-435.
306. Simon N.M., Walton Z.E., Bui E., Prescott J., Hoge E., Keshaviah A., Schwarz N., Dryman T., Ojserkis R.A., Kovachy B., Mischoulon D., Worthington J., DeVivo I., Fava M., Wong K.-K. Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. Psychoneuroendocrinology 2015.
307. Singh I., Rose N. Biomarkers in psychiatry. Nature 2009, 460:202-207.
308. Smalheiser N.R., Lugli G., Rizavi H.S., Torvik V.I., Turecki G., Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012, 7:e33201.
309. Smalheiser N.R., Lugli G., Rizavi H.S., Zhang H., Torvik V.I., Pandey G.N., Davis J.M., Dwivedi Y. MicroRNA expression in rat brain exposed to repeated inescapable shock: differential alterations in learned helplessness vs. non-learned helplessness. Int. J. Neuropsychopharmacol. 2011, 14:1315-1325.
310. Smith K. Mental health: a world of depression. Nature 2014, 515:181.
311. Song M.-F., Dong J.-Z., Wang Y.-W., He J., Ju X., Zhang L., Zhang Y.-H., Shi J.-F., Lv Y.-Y. CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system. J. Affective Disorders 2015, 178:25-31.
312. Søreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J. Clin. Pathol. 2009, 62:1-5.
313. Spielmans G.I., Berman M.I., Linardatos E., Rosenlicht N.Z., Perry A., Tsai A.C. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013, 10:e1001403.
314. Surtees P.G., Wainwright N.W., Pooley K.A., Luben R.N., Khaw K.T., Easton D.F., Dunning A.M. Life stress, emotional health, and mean telomere length in the European Prospective Investigation into Cancer (EPIC)-Norfolk population study. The journals of gerontology. Series A. Biol. Sci. Med. Sci. 2011, 66:1152-1162.
315. Suzuki K., Iwata Y., Matsuzaki H., Anitha A., Suda S., Iwata K., Shinmura C., Kameno Y., Tsuchiya K.J., Nakamura K., Takei N., Mori N. Reduced expression of apolipoprotein E receptor type 2 in peripheral blood lymphocytes from patients with major depressive disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2010, 34:1007-1010.
316. Takahashi N., Nagai Y., Ueno S., Saeki Y., Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett. 1992, 314:23-25.
317. Takebayashi M., Hashimoto R., Hisaoka K., Tsuchioka M., Kunugi H. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J. Neural Transm. 2010, 117:1119-1122.
318. Teyssier J.R., Ragot S., Donzel A., Chauvet-Gelinier J.C. Telomeres in the brain cortex of depressive patients. L'Encephale 2010, 36:491-494.
319. Teyssier J.R., Chauvet-Gelinier J.C., Ragot S., Bonin B. Up-regulation of leucocytes genes implicated in telomere dysfunction and cellular senescence correlates with depression and anxiety severity scores. PLoS One 2012, 7:e49677.
320. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
321. Trivedi M.H., Greer T.L., Church T.S., Carmody T.J., Grannemann B.D., Galper D.I., Dunn A.L., Earnest C.P., Sunderajan P., Henley S.S., Blair S.N. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J. Clin. Psychiatry 2011, 72:677-684.
322. Tsai S.J., Hong C.J., Liou Y.J., Yu Y.W., Chen T.J., Hou S.J., Yen F.C. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2009, 33:637-641.
323. Tsang J., Zhu J., van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol. Cell 2007, 26:753-767.
324. Tsao C.W., Lin Y.S., Chen C.C., Bai C.H., Wu S.R. Cytokines and serotonin transporter in patients with major depression. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2006, 30:899-905.
325. Turner C.A., Akil H., Watson S.J., Evans S.J. The fibroblast growth factor system and mood disorders. Biol. Psychiatry 2006, 59:1128-1135.
326. Tzvetkov M.V., Brockmoller J., Roots I., Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet. Genom. 2008, 18:495-506.
327. Uchida S., Nishida A., Hara K., Kamemoto T., Suetsugi M., Fujimoto M., Watanuki T., Wakabayashi Y., Otsuki K., McEwen B.S., Watanabe Y. Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor. Eur. J. Neurosci. 2008, 27:2250-2261.
328. USPTO, 2013.
329. Varnas K., Halldin C., Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Map. 2004, 22:246-260.
330. Verhoeven J.E., Revesz D., Epel E.S., Lin J., Wolkowitz O.M., Penninx B.W.J.H. Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol. Psychiatry 2014, 19:895-901.
331. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
332. Videbech P., Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 2004, 161:1957-1966.
333. Volk N., Paul E.D., Haramati S., Eitan C., Fields B.K., Zwang R., Gil S., Lowry C.A., Chen A. MicroRNA-19b associates with Ago2 in the amygdala following chronic stress and regulates the adrenergic receptor beta 1. J. Neurosci. 2014, 34:15070-15082.
334. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2002, 27:339-344.
335. Wang K., Zhang S., Weber J., Baxter D., Galas D.J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010, 38:7248-7259.
336. Wang H.-C., Yeh T., Chang H., Gean P., Chi M., Yang Y., Lu R.-B., Chen P. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology 2011, 213:773-779.
337. Wang X., Sundquist K., Hedelius A., Palmér K., Memon A.A., Sundquist J. Circulating microRNA-144-5p is associated with depressive disorders. Clin. Epigenet. 2015, 7:69.
338. Wapinski O., Chang H.Y. Long noncoding RNAs and human disease. Trends Cell Biol. 2011, 21:354-361.
339. Warden D., Rush A.J., Trivedi M., Fava M., Wisniewski S. The STAR*D project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9:449-459.
340. Webster M.J., Knable M.B., O'Grady J., Orthmann J., Weickert C.S. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol. Psychiatry 2002, 7:985-994. 924.
341. Wei F., Patel P., Liao W., Chaudhry K., Zhang L., Arellano-Garcia M., Hu S., Elashoff D., Zhou H., Shukla S., Shah F., Ho C.-M., Wong D.T. Electrochemical sensor for multiplex biomarkers detection. Clin. Cancer Res. 2009, 15:4446-4452.
342. Wei Y.B., Backlund L., Wegener G., Mathe A.A., Lavebratt C. Telomerase dysregulation in the hippocampus of a rat model of depression: normalization by lithium. Int. J. Neuropsychopharmacol. 2015.
343. Weigelt K., Carvalho L.A., Drexhage R.C., Wijkhuijs A., Wit H.d.van Beveren N.J.M., Birkenhäger T.K., Bergink V., Drexhage H.A. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3: ATF3 and PU.1 as important transcription factors. Brain Behav. Immun. 2011, 25:1162-1169.
344. White K.J., Walline C.C., Barker E.L. Serotonin transporters: implications for antidepressant drug development. AAPS J. 2005, 7:E421-E433.
345. Whitney A.R., Diehn M., Popper S.J., Alizadeh A.A., Boldrick J.C., Relman D.A., Brown P.O. Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1896-1901.
346. Wikgren M., Maripuu M., Karlsson T., Nordfjall K., Bergdahl J., Hultdin J., Del-Favero J., Roos G., Nilsson L.G., Adolfsson R., Norrback K.F. Short telomeres in depression and the general population are associated with a hypocortisolemic state. Biol. Psychiatry 2012, 71:294-300.
347. Wojcicki J.M., Heyman M.B., Elwan D., Shiboski S., Lin J., Blackburn E., Epel E. Telomere length is associated with oppositional defiant behavior and maternal clinical depression in Latino preschool children. Transl. Psychiatry 2015, 5:e581.
348. Wolkowitz O.M., Mellon S.H., Epel E.S., Lin J., Dhabhar F.S., Su Y., Reus V.I., Rosser R., Burke H.M., Kupferman E., Compagnone M., Nelson J.C., Blackburn E.H. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress - preliminary findings. PLoS One 2011, 6:e17837.
349. Wolkowitz O.M., Mellon S.H., Epel E.S., Lin J., Reus V.I., Rosser R., Burke H., Compagnone M., Nelson J.C., Dhabhar F.S., Blackburn E.H. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol. Psychiatry 2012, 17:164-172.
350. Wolkowitz O.M., Mellon S.H., Lindqvist D., Epel E.S., Blackburn E.H., Lin J., Reus V.I., Burke H., Rosser R., Mahan L., Mackin S., Yang T., Weiner M., Mueller S. PBMC telomerase activity, but not leukocyte telomere length, correlates with hippocampal volume in major depression. Psychiatry Res. 2015.
351. Wong M.-L., Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2001, 2:343-351.
352. Woody M.L., Gibb B.E. Integrating NIMH research domain criteria (RDoC) into depression research. Curr. Opin. Psychol. 2015, 4:6-12.
353. Xiang L., Szebeni K., Szebeni A., Klimek V., Stockmeier C.A., Karolewicz B., Kalbfleisch J., Ordway G.A. Dopamine receptor gene expression in human amygdaloid nuclei: elevated D4 receptor mRNA in major depression. Brain Res. 2008, 1207:214-224.
354. Xinhua S., Yanfeng W., Mingcai Q., Xiaoquan W., Zhenghua H., Yang L., Jushui S., Hua Z., Jianhong Y., Min L., Liang L., Tiefeng G., Zhongxia S., Yonggui Y. Tryptophan hydroxylase 2 gene is associated with major depressive disorder in a female Chinese population. J. Affective Disorders 2011, 133:619-624.
355. Xu Y., Li F., Zhang B., Zhang K., Zhang F., Huang X., Sun N., Ren Y., Sui M., Liu P. MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophrenia Res. 2010, 119:219-227.
356. Xu Y., Liu H., Li F., Sun N., Ren Y., Liu Z., Cao X., Wang Y., Liu P., Zhang K. A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform. J. Affective Disorders 2010, 127:332-336.
357. Yamamoto H., Gurney M.E. Human platelets contain brain-derived neurotrophic factor. J. Neurosci. 1990, 10:3469-3478.
358. Yee C.M., Javitt D.C., Miller G.A. Replacing dsm categorical analyses with dimensional analyses in psychiatry research: the research domain criteria initiative. JAMA Psychiatry 2015, 72:1159-1160.
359. Yokoyama Y., Takahashi Y., Morishita S., Hashimoto M., Niwa K., Tamaya T. Telomerase activity in the human endometrium throughout the menstrual cycle. Mol. Hum. Reprod. 1998, 4:173-177.
360. Yue D., Liu H., Huang Y. Survey of computational algorithms for microRNA target prediction. Curr. Genom. 2009, 10:478-492.
361. Zarate C.A., Manji H.K. Riluzole in psychiatry: a systematic review of the literature. Expert Opin. Drug Metab. Toxicol. 2008, 4:1223-1234.
362. Zeng J., Kitayama I., Yoshizato H., Zhang K., Okazaki Y. Increased expression of corticotropin-releasing factor receptor mRNA in the locus coeruleus of stress-induced rat model of depression. Life Sci. 2003, 73:1131-1139.
363. Zhang X., Gainetdinov R.R., Beaulieu J.M., Sotnikova T.D., Burch L.H., Williams R.B., Schwartz D.A., Krishnan K.R., Caron M.G. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005, 45:11-16.
364. Zhang D., Cheng L., Craig D.W., Redman M., Liu C. Cerebellar telomere length and psychiatric disorders. Behav. Genet. 2010, 40:250-254.
365. Zhang L., Zhang J., Sun H., Liu H., Yang Y., Yao Z. Exposure to enriched environment restores the mRNA expression of mineralocorticoid and glucocorticoid receptors in the hippocampus and ameliorates depressive-like symptoms in chronically stressed rats. Curr. Neurovasc. Res. 2011, 8:286-293.
366. Zheng P., Wang Y., Chen L., Yang D., Meng H., Zhou D., Zhong J., Lei Y., Melgiri N.D., Xie P. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol. Cell Proteomics 2013, 12:207-214.
367. Zhou R., Yuan P., Wang Y., Hunsberger J.G., Elkahloun A., Wei Y., Damschroder-Williams P., Du J., Chen G., Manji H.K. Evidence for selective micrornas and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2008, 34:1395-1405.
368. Zhou Q.G., Hu Y., Wu D.L., Zhu L.J., Chen C., Jin X., Luo C.X., Wu H.Y., Zhang J., Zhu D.Y. Hippocampal telomerase is involved in the modulation of depressive behaviors. J. Neurosci. 2011, 31:12258-12269.
369. Zhou L., Xiong J., Lim Y., Ruan Y., Huang C., Zhu Y., Zhong J.H., Xiao Z., Zhou X.F. Upregulation of blood proBDNF and its receptors in major depression. J. Affective Disorders 2013, 150:776-784.
370. Zill P., Büttner A., Eisenmenger W., Bondy B., Ackenheil M. Regional mRNA expression of a second tryptophan hydroxylase isoform in postmortem tissue samples of two human brains. Eur. Neuropsychopharmacol. 2004, 14:282-284.
371. Zovoilis A., Agbemenyah H.Y., Agis-Balboa R.C., Stilling R.M., Edbauer D., Rao P., Farinelli L., Delalle I., Schmitt A., Falkai P., Bahari-Javan S., Burkhardt S., Sananbenesi F., Fischer A. microRNA-34c is a novel target to treat dementias. EMBO J. 2011, 30:4299-4308.